NCT02907528 is a NA clinical trial of Bone in Chronic Periodontitis, sponsored by Ohio State University.

Who is sponsoring NCT02907528?

NCT02907528 is sponsored by Ohio State University.

What drugs are being tested in NCT02907528?

Interventions in NCT02907528: Bone, EMD.

What condition does NCT02907528 study?

NCT02907528 studies Chronic Periodontitis.

Is NCT02907528 still recruiting?

NCT02907528 is currently completed. Last updated 1 March 2021.

Last reviewed 2021-03-01 · How we verify

NCT02907528

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Furcation Therapy With Enamel Matrix Derivative: Effects on the Subgingival Microbiome

Completed NA Last updated 1 March 2021

What this trial tests

NA trial testing Bone in Chronic Periodontitis in 39 participants. Completed in 1 January 2016.

Timeline

1 January 2014

Primary endpoint
1 December 2014

1 January 2016

Quick facts

Lead sponsor	Ohio State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	39
Start date	1 January 2014
Primary completion	1 December 2014
Estimated completion	1 January 2016

Drugs / interventions tested

Bone — full drug profile →
EMD — full drug profile →

Conditions studied

Chronic Periodontitis — all drugs for Chronic Periodontitis →

Sponsor

Ohio State University

Who can join

Adults 21 to 75, any sex, with Chronic Periodontitis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Shifts in the subgingival microbiome at 3 and 6 months in response to the interventions
Time frame: 6 months
Subgingival microbial plaque samples will be collected at baseline and at the 3 and 6-month re-evaluation visits. Bacterial samples will be removed from the paper points by adding 200µl of phosphate buffered saline (PBS) and vortexing for 1 minute. The paper points were then removed, and DNA isolated using a Qiagen MiniAmp kit (Valencia, CA) according to the manufacturer's instructions. Multiplexe

Sponsor's own description

Objective: To clinically evaluate mandibular furcation treated with Beta tricalcium phosphate/hydroxyapatite (βTCP/HA) isolated or combined with enamel matrix derivative (EMD + βTCP/HA) and EMD alone. Material and Methods: 39 patients, presenting at least one mandibular class II furcation defect, probing pocket depth (PPD) ≥ 4 mm and bleeding on probing, were included. The defects were assigned to the βTCP/HA group 1 (n = 13); open-flap debridement (OFD) + βTCP/HA filling; βTCP/HA + EMD group 2 (n = 13); OFD + βTCP/HA + EMD filling; and EMD group 3 (n = 13) OFD + EMD filling. Plaque (PI) and gingival index (GI), PPD, relative gingival margin position (RGMP), vertical and horizontal attachment level (RVCAL and RHCAL), and furcation diagnosis were evaluated at baseline, 6 and 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Periodontitis

Currently open trials in the same condition.

NCT06893107 — Study on Treatment Results and Bone Changes After Replanting Severely Affected Teeth - A Before-and-After Study. · NA · recruiting
NCT05275192 — Utilization of a Videoscope in Periodontal Regeneration · NA · recruiting
NCT03741374 — Minimally-invasive Non-surgical Therapy of Intrabony Defects · NA · active not recruiting
NCT03553095 — Comparing Inflammatory Markers in Patients With and Without Depression With Chronic Periodontitis · NA · active not recruiting

Other Ohio State University trials

Trials by the same sponsor.

NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02907528 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University
Last refreshed: 1 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02907528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing